Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

nk/T-cell Lymphoma · Newly Diagnosed · Advanced Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

ChinaPLAGH, Beijing, Haidian, China
Contact: Study coordinator (Yu Zhao, Graduate) · 010-66937232
Contact: Study coordinator (Sai Huang, Graduate) · 010-66937232

Study leads

Yu Zhao, Graduate
Principal Investigator
Chief
Sai Huang, Graduate
Principal Investigator
Attending doctor

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Lymphoma

Abroad (travel likely)RecruitingPHASE2

Miami, United States · Chicago, United States

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Lymphoma

Abroad (travel likely)RecruitingPHASE2

Seoul, South Korea

Registry of Older Patients With Cancer

Chronic Myeloproliferative Disorders · Cognitive/Functional Effects · Leukemia

Abroad (travel likely)Recruiting

Boone, United States · Chapel Hill, United States

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Leukemia · Hematopoetic Stem Cell Transplantation · Donor Lymphocyte Infusion

Abroad (travel likely)RecruitingEARLY_PHASE1

Tucson, United States